StonvexLoading…
StonvexStonvexStonvexCore line items from AMCX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $542.13M | $2.31B | $1.72B | $1.16B |
Operating Income | $31.26M | $133.32M | $184.18M | $128.67M |
Net Income | $-18.87M | $89.40M | $144.87M | $68.34M |
EPS (Diluted) | $-0.43 | $1.66 | $2.63 | $1.25 |
Total Assets | $3.87B | $3.94B | $4.21B | $4.42B |
Total Liabilities | $2.89B | $2.92B | $3.07B | $3.35B |
Cash & Equivalents | $552.14M | $502.38M | $716.84M | $866.41M |
Free Cash Flow OCF − CapEx | $64.81M | $272.37M | $231.92M | $189.93M |
Shares Outstanding | 43.63M | 56.59M | 56.41M | 56.48M |